TresActio accepted to Novo Nordisk BII

The TresActio team has been accepted to the Novo Nordisk Bioinnovation Institutes Business Accelerator program. Focusing on commercial development of IP generated at Siemens, the team has now raised close to 1MDKK. Congratulations to the entire team on acceptance to the highly competitive program.